Monday, October 7, 2013
Aspain | Acetylsalicylic acid
Aspain
Acetylsalicylic acid 300 mg/tab.
Company Name
Alexandria
Therapeutic Group
NON-NARCOTIC ANALGESICS
Pharmaceutical form
Tablet
Package
200 Tablets
Indications
- Headache - Muscle pain - Toothache - Menstrual pain - Pain and fever of colds - Minor pain of arthritis
Warning & Precautions
- The physician must be consulted when aspirin is used for children less than 12 years old because it may cause symptoms of Reye syndrome especially in cases of influenza and chicken box . Pregnancy: Concerning the harmful effect of acetylsalicylic acid ( Aspirin ) in the last three months of pregnancy due to the possibility of prolonging the period of pregnancy and the increased risk of antepartum and postpartum haemorrhage as well as the risk of bleeding tendency in the new born. Not to use the drug in high doses during the last three months of pregnancy. Nursing mothers : Nursing mothers should avoid using aspain because salicylate is execreted in breast milk
Product Type
Human
Dosage
As directed by the physician or as follows: Adults and children 12 years and over : 1 or 2 tablets every 4 hours, not to exceed 12 tablets in 24 hours. Children under 12 years : Consult a doctor.
Adverse Reactions
Stop use if : - Allergic reactions - Pain gets worse or lasts for more than 10 days - Fever lasts for more than 3 days - Ringing in the ears or loss of hearing occurs - Redness or swelling is present
Contra Indications
The drug is contraindicated for patients suffer from : - Allergy to aspirin or any other pain relievers / fever reducers - stomach problems ( Such as heartburn , stomach pain ) that continue or come back - Bleeding problems - ulcers - asthma Ask a doctor before use if you are taking a prescription drug for : - Anticoagulation ( blood thinning ) - Gout - Diabetes - Arthritis
Drug Interactions
/
5
EgyDrug Index: Aspain | Acetylsalicylic acid
Aspain Acetylsalicylic acid 300 mg/tab. Company Name Alexandria Therapeutic Group NON-NARCOTIC ANALGESICS Pharmaceutical form T...
No comments:
Post a Comment